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Abstract We report the management of refractory status epilepticus (SE) by using continuous
intravenous infusions of lidocaine in a previously healthy 15-year-old girl with a
“catastrophic encephalopathy” in whom a diagnosis of febrile infection-related epilepsy
syndrome was supposed. One week after a banal pharyngitis and fever, the patient
presented confusion and intractable clusters of seizures. Although she underwent
multiple examinations investigating all possible etiologies (intracranial infection,
autoimmune disease, or toxic and metabolic illness), all results were negative except
a feeble positivity to Mycoplasma pneumoniae serum antibodies. SE was initially treated
with benzodiazepine followed by administration of barbiturates and subsequent
induction of coma because of refractory SE; different antiepileptic drugs (AEDs) were
given at different times in a period of 6 weeks but clinical and electroencephalographic
improvements were achieved only after continuous infusion of lidocaine. When she
recovered from SE, the patient developed severe psychomotor and cognitive im-
pairment associated with cerebral atrophy. Treatment with lidocaine or other alterna-
tive drugs in cases of prolonged SE should be taken into account as soon as it becomes
clear that the clinical condition is refractory to common AEDs included in available
guidelines for SE treatment, to improve the bad outcome of this severe condition, at
least limiting the negative effects of prolonged high metabolic demand due to
continuous epileptiform activity and/or the possible negative effects of prolonged
burst-suppression coma.
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Introduction
Febrile infection-related epilepsy syndrome (FIRES) is an
infection-related epileptic encephalopathy described by
many authors with different names1: new-onset refractory
status epilepticus (NORSE), devastating epileptic encepha-
lopathy in school age children (DESC), acute encephalitis with
refractory repetitive partial seizures (AERRPS), fever-induced
refractory epileptic encephalopathy in school age children,
and FIRES. Common features are the acute onset of refractory
seizures occurring in previously healthy children after a banal
febrile infection of different origins and progressive mental
deterioration with bad outcome. The pathogenesis of this
entity is still unknown even if immune-mediated mecha-
nisms have been suggested2,3 and all extensive treatment
efforts, including intensive care, are fruitless leading to a
severe outcome. The severe acute presumed symptomatic
refractory status epilepticus (SE) that develops at onset is
associated with a highmorbidity rate in terms of seizures and
cognition at follow-up. It is still unclear if this condition
represents a specific nosologic entity per se or a particularly
severe refractory SE due to specific etiologies, even if some
series have been published to define this entity.4,5 Recently
published articles focus their attention on therapy, proposing
ketogenic diet,6,7 and suggest a role of inflammation process-
es in determining SE.3
Our report aims to discuss the treatment and follow-up of
prolonged super refractory SE, as defined by Shorvon, as SE
that continues or recurs 24 hours or more after the onset of
anesthetic therapy, with lidocaine, a possible alternative
drug in SE8 in a 15-year-old girl whose clinical picture was
suggestive of FIRES.
Case Report
A 15-year-old girl was admitted to our emergency depart-
ment for altered mental status, confusion, physical agitation,
and light neck stiffness. The previous week she experienced
fever, asthenia, and upper respiratory tract infection treated
with paracetamol and antibiotics. On admission, Glasgow
Coma Scale was 8 and she presented mild increase in body
temperature (37.9°C). She subsequently presented intracta-
ble SE with clusters of seizures clinically characterized
by generalized tonic–clonic jerks, focal myoclonic seizures
involving both sides alternatively and lasting from few
seconds to several minutes. Initial electroencephalography
(EEG) showed diffuse slow delta activity. In the hypothesis of
infectious meningoencephalitis, antibiotic and antiviral
reatment was initially started, without clinical improvement.
SE was treated initially with diazepam, midazolam, and
phenobarbital at weight-appropriate dosages without efficacy.
Barbiturate coma with thiopental sodium in the intensive
care unit (ICU) was then induced. EEG showed suppression
burst features with suppression periods lasting 3 to 4 seconds
and persistent electroclinical seizures, characterized by
diffuse bilateral clonia. Initial improvement of EEG pattern
led to reduction of barbiturate coma with reappraisal of SE
so phenytoin (PHE), sodium valproate (VPA), adrenocortico-
tropic hormone, pyridoxine, and levetiracetam (LEV) at ap-
propriate dosage were introduced at different times in a
period of 6weeks, without significant electroclinical improve-
ment (►Fig. 1A). Lidocaine was then started at a dose of
1.25 mg/kg/h resulting in a progressive resolution of SE
and EEG improvement from the 1st day of administration
(►Fig. 1B), allowing the barbiturate coma to be completely
removed in the subsequent days. She was discharged from
the ICU with intravenous lidocaine, VPA, and LEV. Lidocaine
was tapered off 6 months after and her latest treatment is a
polytherapy with Carbamazepine, Clobazam, and Lacosamide
with persisting seizures (►Fig. 2). Even in absence of a clear
immunological etiology, a trial with intravenous immuno-
globulin G was subsequently tried after SE, without clinical
improvement on seizures. At 18 months follow-up she pre-
sented moderate cognitive disability (intelligence quotient
[IQ]: 55), emotional instability, and a significant psychomotor
deterioration. At clinical examination, she was able to walk
with partial weight bearing, showed tendon retraction
and signs of peripheral neuropathy due to nerve compression
from prolonged lying. Partial seizures with secondary gener-
alization persisted with visual sensation, scotoma, gaze
deviation, overflow of saliva, loss of consciousness, chewing
automatism, generalized clonia, sometimes followed by
vomiting; seizure frequency reduced over time without
seizure-free periods longer than 15 to 20 days. Her EEG
Fig. 1 (A) Electroencephalography (EEG) during status epilepticus: high pass filter: 0.530 Hz; low pass filter: 30 Hz; and gain: 150 microV/cm;
(B) EEG during lidocaine infusion: high pass filter: 0.530 Hz; low pass filter: 30 Hz; and gain: 150 microV/cm.
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pattern showed diffuse slow activity with multifocal epilepti-
form discharges.
Neuroimaging and laboratory investigations: brain mag-
netic resonance imaging (MRI) was initially normal except
from bilateral mastoiditis; 1 month after vasogenic edema in
external capsule, amygdalae, putamen, and lingual gyrus was
evident; 2 months after edema was reduced in putamen and
insulae but a concomitant worsening of signal alteration in
subcortical white matter was observed. Brain MRIs per-
formed after 6 and 12 months then showed diffuse cerebral
atrophy. An extensive infectious, metabolic, and immunolog-
ical work up was performed: cerebrospinal fluid (CSF), cutis,
urine, feces, and blood were tested for infectious, metabolic,
and immunological etiologies, resulting in a feeble positivity
toMycoplasma pneumoniae serum antibodies, not confirmed
by polymerase chain reaction on the CSF.
Discussion
We report a case in which a diagnosis of FIRES was supposed
as the patient, a previously healthy girl, after a banal upper
respiratory tract infection, developed refractory SE, for which
extensive diagnostic work up was negative. In our patient, a
feeble positivity to Mycoplasma pneumoniae serum antibod-
ies was found and only subsequent MRI showed progressive
anomalies, such as diffuse cerebral atrophy, probably due to
prolonged SE. At follow-up, cognitive level was poor associat-
ed with psychiatric problems. Our patient presented a super
refractory SE lasting approximately 2 months that, despite
several antiepileptic drugs (AEDs), achieved full control in
a short time only after lidocaine was given, even at lower
doses than reported in literature. Like ours, some studies in
the literature report the use of lidocaine in FIRES: recently
some positive outcome in terms of seizure control has been
described:9 these authors administered lidocaine at high dose
in association with high dose phenobarbital and topiramate,
with good seizure control.
Lidocaine is a local anesthetic drug that exerts its action
blocking ionic currents on voltage-gated sodium channels in
nerve cells during abnormal membrane depolarizations,
currently used as an antiarrhythmic drug (class IB). The
mechanism of action is unclear, it may have membrane-
stabilizing effects and a central local anesthetic action on
the inhibitory pathway fibers involved in direct cortical
stimulation.
To date, no controlled trial for lidocaine in SE has been
published. Despite many reports in literature since 1955 on
the use of lidocaine in SE, this drug is not included in many
current available protocols of SE treatment, probably because
of its not well-defined efficacy on SE and its potentially
serious adverse effects, in particular, in pediatric population.
In Italian guidelines for SE treatment in adults,8 lidocaine is
mentioned, with a grade C, level 4 of evidence, as an alterna-
tive treatment in refractory SE when other therapeutic
options have failed; in guidelines for treatment of SE in
children, this drug is cited even if its use is not recommended
due to scarce literature data on its use in pediatric population.
In addition, no standardized procedures for lidocaine in SE
have ever been reported in literature. Its usemust be carefully
evaluated in any single case, considering all prognostic fac-
tors, and must be done by expert physicians as, among other
possible adverse events, at blood concentration exceeding
10 ug/mL it may be proconvulsant.8
As reported bymany studies on pediatric series,10 it seems
that lidocainemay be particularly effective in those situations
wherefirst line AEDs (benzodiazepine, PHT, and barbiturates)
for SE have been ineffective, exerting its action with some
advantages, as the lower risk of respiratory depression and
subsequent need of intubation. In addition, it is effective in a
short time (distribution half-time: 8–17 minutes) even if this
last one may also represent a disadvantage as, to maintain its
effectiveness, it has to be administered in continuous infusion
at a reported dosage of 2 to 3.5 mg/kg/h after a bolus of 1.5 to
2 mg/kg, given at a maximum rate of 50 mg/min.8,10
FIRES is a “catastrophic” and “devastating” encephalopa-
thy that leads to a super refractory SE with a bad outcome as
in the case reported, a previously healthy girl who developed
severe psychomotor deterioration, cognitive impairment,1,5
and emotional instability. Given to the quick effective re-
sponse achieved with lidocaine we presume that, if this drug
was introduced earlier, probably the duration of SE could
have been shorter with a better long-term outcome.
Conclusions
To date, treatment algorithms in childhood refractory SE are
characterized by the lack of randomized controlled trials and
remain mostly empirical with different therapeutic ap-
proaches, mainly derived from adult guidelines for SE. In
our experience, the use of lidocaine, based onmany reports or
case series available in the literature, has been effective in
controlling SE.8,10 In cases of super refractory SE, we suggest
considering a therapeutic approach with other “alternative”
drugs as soon as it becomes clear that the clinical condition is
refractory to conventional AEDs included in available
Fig. 2 Clinical course of the patient: timing of AEDs introduction and
subsequent variations. AED, antiepileptic drugs; ACTH, adrenocorti-
cotropic hormone; B6VIT, B6 vitamin; LEV, levetiracetam; M, Mida-
zolam; PB, phenobarbital; PHE, phenytoin; TPS, sodium thiopental;
VPA, sodium valproate.
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guidelines for SE treatment, to reduce the worsening of long-
term outcome due to cerebral sufferance subsequent to
prolonged epileptic discharges and/or the possible negative
effects of prolonged burst-suppression coma.
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